< Back to previous page
Researcher
Fred Van Leuven
- Disciplines:Genetics, Systems biology, Medical imaging and therapy, Molecular and cell biology, Other paramedical sciences
Affiliations
- Department of Human Genetics (Department)
Member
From1 Oct 1999 → 30 Sep 2014
Projects
1 - 9 of 9
- Influence of chronic oligemia on neurovascular defects and their relation to the onset and development of neurodegeneration: in vivo evaluation of neurovascular response capacity and metabolism in an Alzheimer mouse model.From1 Oct 2013 → 17 Sep 2019Funding: FWO fellowships
- Mechanisms underlying protein tau-mediated neurodegeneration: combining transgenic mouse models and AAV vectors.From1 Oct 2010 → 30 Sep 2014Funding: BOF - Concerted Research Project from 1994
- Differential analysis of the physiological functions of GSK-3a/b isozymes in brain in vivo.From1 Oct 2009 → 30 Jun 2010Funding: BOF - Other initiatives
- Development and validation of active and passive immunotherapy targeted at protein Tau in transgenic mouse models for Alzheimer's diseaseFrom1 Oct 2008 → 13 Sep 2013Funding: Own budget, for example: patrimony, inscription fees, gifts
- Tau-based Mabs and Vaccines: development and pre-clinical assessment of diagnostic and therapeutic potential in transgenic models for Tauopathy & Alzheimer's disease.From1 Oct 2008 → 30 Sep 2012Funding: IOF - Industrial Research Fund
- NEURO.GSK3: GSK3 in neuronal plasticity and neurodegeneration: basic mechanisms and pre-clinical assessment.From1 Oct 2008 → 31 Dec 2011Funding: Health
- The physiological and pathological contribution of GSK3 isozymes in normal mice and transgenic Alzheimer mice models.From1 Sep 2008 → 1 Jan 2010Funding: Own budget, for example: patrimony, inscription fees, gifts
- Inter-relations of protein Tau, GSK3 and Nectin-3 in synaptic structure and plasticity in the hippocampus of mouse models for Alzheimer's diseaseFrom1 Feb 2008 → 28 Jun 2013Funding: Own budget, for example: patrimony, inscription fees, gifts
- Analysis of adaptations of cytoskeleton, dendritic spines and synaptic plasticity in relation to physiological and pathological phosphorylation of protein tau in vivo.From1 Jan 2008 → 31 Dec 2011Funding: FWO research project
Publications
1 - 10 of 86
- "Endothelial Antibody Factory" at the Blood Brain Barrier: Novel Approach to Therapy of Neurodegenerative Diseases(2022)
Authors: Fred Van Leuven
- Unraveling the Effects of GSK-3β Isoform Modulation against Limbic Seizures and in the 6 Hz Electrical Kindling Model for Epileptogenesis(2022)
Authors: Fred Van Leuven
Pages: 796 - 805 - Annexin A1 restores cerebrovascular integrity concomitant with reduced amyloid-β and tau pathology(2021)
Authors: Fred Van Leuven
Pages: 1526 - 1541 - Quantitative Assessment of Age-Associated Alterations in Brain Vasculature in Wild-Type Mice and in Bigenic Mice that Model Alzheimer's Disease(2020)
Authors: Kristof Govaerts, Tom Dresselaers, Fred Van Leuven, Uwe Himmelreich
Pages: 578 - 586 - The quantitative analysis of vascular and morphological abnormalities in mouse models of neurodegenerative disease(2019)
Authors: Kristof Govaerts, Uwe Himmelreich, Fred Van Leuven, Tom Dresselaers
- Regional vulnerability and spreading of hyperphosphorylated tau in seeded mouse brain(2019)
Authors: Fred Van Leuven, Sarah Baatout
Pages: 398 - 409 - Identification of GSK-3 as a Potential Therapeutic Entry Point for Epilepsy(2019)
Authors: Camila Esguerra, Fred Van Leuven, Peter de Witte
Pages: 1992 - 2003 - Longitudinal assessment of cerebral perfusion and vascular response to hypoventilation in a bigenic mouse model of Alzheimer's disease with amyloid and tau pathology(2019)
Authors: Kristof Govaerts, Fred Van Leuven, Uwe Himmelreich, Tom Dresselaers
- GSK3β activity alleviates epileptogenesis and limits GluA1 phosphorylation(2019)
Authors: Fred Van Leuven
Pages: 377 - 387 - TauBI or not TauBI: what was the question?(2018)
Authors: Fred Van Leuven
Pages: 2536 - 2539
Patents
1 - 10 of 10
- Humanized tau antibody (Inventor)
- Pharmaceutical composition (Inventor)
- Methods of diagnosing diseases caused by or associated with neurofibrillary tangles by phosphospecific antibodies recognising tau (Inventor)
- Antibodies to phosphorylated tau aggregates (Inventor)
- Phosphospecific antibodies recognising tau (Inventor)
- Methods of diagnosing tau-protein-associated disease (Inventor)
- Phosphospecific antibodies recognising tau (Inventor)
- ANTIBODIES RECOGNISING PHOSPHO-TAU (Inventor)
- Pharmaceutical composition (Inventor)
- Phosphospecific antibodies recognising tau (Inventor)